Pleiotropic effects of erythropoietin;Pleotropni učinci eritropoetina

Acta Medica Croatica

Volumn 63, Issue SUPPL. 1, 2009, Pages 46-53

  Petar, K E S ^a   Bašić Jukić, Nikolina ^a   Furić Čunko, Vesna ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Brain; Erythropietin; Erythropietin receptor; Heart; Kidney; Neuron; Pleiotropic effects; Vascular system

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CREATINE KINASE; CYTOTOXIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FUROSEMIDE; GELATINASE A; GLUCOSE TRANSPORTER 1; HEMOGLOBIN; HEPATOCYTE NUCLEAR FACTOR 4; HYPOXIA INDUCIBLE FACTOR 1BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MYOD1 PROTEIN; MYOGENIC FACTOR 5; N(G) NITROARGININE METHYL ESTER; PROTEIN FOS; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; SMAD3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR TAL1; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ANGIOGENESIS; APOPTOSIS; BLUNT TRAUMA; BRAIN; BRAIN INJURY; BRAIN PROTECTION; BURST FORMING UNIT E; CD34 SELECTION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING UNIT E; CONFERENCE PAPER; CYTOTOXICITY; ENDOTHELIUM; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOXIA; IN VITRO STUDY; ISCHEMIA; NONHUMAN; PLEIOTROPY; RENAL PROTECTION; REPERFUSION INJURY; RETINA; SIGNAL TRANSDUCTION; SPINAL CORD; STROKE; TISSUE; TISSUE REPAIR; UTERUS;

EID: 77149174848     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Miyake T, Kung, CK,Goldwasser, E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-5564.
2. Lin FK. i sur. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 98582; 7580-7584.
3. Jacobs K, i sur. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-810.
4. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Yi. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Molecular Med 2008; 10: 1-23.
5. Dame C, Fahnenstich H, Freitag P, i sur. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998; 92: 3218-3225.
6. Obara N, Suzuki N, Kim K i sur. Repression via theGATAbox is essential for tissue-specific erythropoietin gene expression. Blood 2008; 111: 5223-5232.
7. Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem 2004; 385: 223-230.
8. Anagnostou A, i sur. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994; 91: 3974-3978.
9. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126: 3597-3605.
10. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43: 40-49.
11. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31.
12. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Role of erythropoietin in the brain. Crit Rev Oncol Hematol 2007; 64: 159-171.
13. Ribatti D, i sur. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93: 2627-2636.
14. Chong ZZ, Kang, JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106: 2973-2979.
15. Beleslin-Cokic BB, i sur. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial ceils. Blood 2004;104: 2073-2080.
16. Defouilloy C, Teiger E, Sediame S, i sur. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. Am J Respir Crit Care Med 1998;157: 1452-1460.
17. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 2003;42: 142-149.
18. Bahlmann FH, Boehm SM, Menne J i sur. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926.
19. Turker G, Nazan S, Ayse Sevim G, Hale U. The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants. Am J Perinatol 2005; 22: 449-455.
20. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis 1995;26: 202-208.
21. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye 2006; 20: 546-552.
22. Calvillo L, i sur. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806.
23. Tada H, i sur. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 2006; 71: 466-477.
24. Parsa CJ, Matsumoto A, Kim J i sur. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
25. Rui T, Feng Q, Lei M, i sur. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005; 65, 719-27.
26. Westenbrink BD, i sur. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28: 2018-27.
27. Masuda S, i sur. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994; 269: 19488-93.
28. Marti HH, i sur. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666-676.
29. Studer, Csete M, Les SH, i sur. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 2000; 20: 7377-7383.
30. Bernaudin M, i sur. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 2002; 22: 393-403.
31. Grimm C, i sur. HIF-1-inducedcrythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002; 8: 718-24.
32. Xenocostas A, i sur. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005; 61,189-95.
33. Van der Meer P, Voors AA, Lipsic E, i sur. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44: 63-7.
34. Silvenberg DS, Wexler D, Sheps D, i sur. The effect of correction of mild anaemia in severe, resistant congestive heart failure using subcutaneous erythoropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
35. Namiuchi S, Kagaya Y, Ohta J, i sur. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45: 1406-12.
36. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000; 15: 225-9.
37. Ehrenreich H. et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007;130: 2577-88.
38. Ehrenreich H. et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007; 12: 206-20.
39. Ehrenreich H, Hasselblatt M, Dembowski C i sur. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
40. De Groot K, Bahlmann FH, Sowa J, i sur. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66: 641-6.
41. Kes P. Povoljni učinci liječenja bubrežne anemije u ranim stadijima kroničnog zatajenja bubrega. Liječ Vjesn 2002; 124: 108-9.
42. Slivenberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003; 18: 7-12.
43. Kes P, Brunetta B. Treba li potpuno ispraviti anemiju u bolesnika s kroničnim zatajenjem bubrega? Liječ Vjesn 2002; 124: 225-7.
44. Mann JFE, Eknoyan G. Benefits of early anaemia treatment in patients with renal Insufficiency. NDT 2000; 15(Suppl. 3): S1-S44.
45. Kes P, Bašić-Jukić N, Jurić I, Bašić-Kes V. Srčano-bubrežni sindrom i eritropoetin. Acta Med Croatica 2008; 62(Suppl 1): 21-31.